研究人員正在尋找治療慢性淋巴細胞白血病（CLL）或小淋巴細胞淋巴瘤（SLL）患者的新方法。CLL 和 SLL 是血癌的類型。研究人員想知道，與接受本研究標準治療的患者相比，接受 nemtabrutinib 的患者是否能活得更久而不出現癌症生長、擴散或復發（無惡化存活期）。
適應症：Chronic Lymphocytic Leukemia、Small Lymphocytic Lymphoma
收案條件
納入條件
- Confirmed diagnosis of chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL) and active disease clearly documented to have a need to initiate therapy
- Has previously untreated CLL/SLL participants without tumor protein 53 (TP53) aberrations and documented 11q status and immunoglobulin heavy chain gene (IGHV) mutational status
- The ability to swallow and retain oral medication
排除條件
- Has active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection
- Has gastrointestinal dysfunction that may affect drug absorption (eg, gastric bypass surgery, gastrectomy)
- Has known additional malignancy that is progressing or has required active treatment within the past 3 years, except basal cell carcinoma of skin, squamous cell carcinoma of skin, or carcinoma in situ (eg, breast carcinoma, cervical cancer in situ) that have undergone potential curative therapy
- Has history of severe bleeding disorders
- Has not adequately recovered from major surgery or has ongoing surgical complications
收案條件維持 ClinicalTrials.gov 原始英文登錄資料，實際收案資格以研究團隊的正式評估與受試者同意書為準。資料來源：ClinicalTrials.gov，每兩週自動更新，最後同步：2026年10月8日。